Prodded by patent cliff & increasing competition, it files application for foray into injectible oncology segment.
Says company yet to file audited accounts, without which it can't proceed.
Firms could lose licence if products not launched within 6 months of approval.
Executives caused loss of Rs 11 cr, according to police SIT.
An interview with Ranbaxy CEO and MD Arun Sawhney on the changes in the past four years and how the company plans to address the US concerns.
SFIO official refuses to reveal the nature of additional charges found during investigation.
Sharad Pawar says final draft will go to Cabinet before Tuesday.
Company refuses to comment, says 'matters internal to organisation'
Another cap for imported insulin; domestic manufacturers cry foul.
FinMin had objected and wanted existing cost-plus method retained.
CCI to examine competition part of deals, RBI prudential aspects.
While the peak holiday season failed to bring in much business to the hotel industry, the online travel booking space has done reasonably well.
Work to begin after that on corrective measures to meet US regulator's requirements.
USFDA has extended the timeline for granting tentative approval to generic drug applications filed under Para IV of its rules by 10 months.
Sun Pharma could have to withdraw cancer drug as J&J re-enters after temporary eclipse
Now, the companies need to get National Pharmaceutical Pricing Authority's nod for changing medicine composition. If they flout norms, government will take penal action.
Maruti Suzuki India Limited (MSIL), which witnessed labour unrest at its Manesar facility, is set to complete the process of regularisation of contract workers at the unit by November-end.
Going all out to market the all new Alto 800, pricing the base variant of the new car lower than the outgoing model, Maruti Suzuki India Ltd (MSIL), today said it will start exporting the car from Gujarat's Mundra port from December this year. The first export market is likely to be Chile in South America.
GoM had proposed a new pricing mechanism, but judges had said at an earlier hearing the current formula should stay.
Ranbaxy was scheduled to launch its drug on September 21, the day Diovan's patent expired.
© 2026 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances